|
A more rational approach to drug design
|
De Novo is a world leader in in-silico, de novo drug design.
De Novo’s technology offers the following advantages to drug developers:-
- lower cost – in-silico design reduces wasted effort in synthesis and HTS
- rapid – typically less than 6 months target to hits
- lower molecular weight hits – allows greater scope for medicinal chemists to optimise molecules
- novel – explore trillions of drug like molecules
- patentable hit molecules – composition of matter claims free from existing IP
De Novo’s technology is derived from a substantial body of research over thirty years in the Department of Pharmacology at the University of Cambridge.
Learn More
|
